Abstract
From the prospective of a major oncology center in the United States, somatostatin analog radiopeptides currently have limited diagnostic and therapeutic utility. Diagnostic modalities utilitizing Somatostatin Receptor Imaging are now commercially available and the role of this type of method is currently being evaluated. Unlike the unique properties of thyroid tissue facilitating I-131 uptake, targeting of other tissues has required a carrier for the nuclide. Somastostatin peptide analogs have proved attractive based on the ubiquity of distribution and up-regulation in diseased tissue but prospective data is currently scarce. Interest in therapeutic applications of somatostatin analogs as carriers of yttrium, indium and more recently rhenium have resulted in trials with these agents both for endocrine and non-endocrine tumors. At this time, insufficient data exists to justify the indication of “first-line” therapy. The principles of Somatostatin Receptor Imaging and radiotherapy are discussed in this article along with the current status of these modalities in clinical practice as viewed by the author.
Keywords: therapeutic applications, somatostatin receptor, first-line therapy, neoplastic tissues, peptide receptor imaging and therapy
Current Pharmaceutical Design
Title: Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Volume: 8 Issue: 20
Author(s): Donald A. Podoloff
Affiliation:
Keywords: therapeutic applications, somatostatin receptor, first-line therapy, neoplastic tissues, peptide receptor imaging and therapy
Abstract: From the prospective of a major oncology center in the United States, somatostatin analog radiopeptides currently have limited diagnostic and therapeutic utility. Diagnostic modalities utilitizing Somatostatin Receptor Imaging are now commercially available and the role of this type of method is currently being evaluated. Unlike the unique properties of thyroid tissue facilitating I-131 uptake, targeting of other tissues has required a carrier for the nuclide. Somastostatin peptide analogs have proved attractive based on the ubiquity of distribution and up-regulation in diseased tissue but prospective data is currently scarce. Interest in therapeutic applications of somatostatin analogs as carriers of yttrium, indium and more recently rhenium have resulted in trials with these agents both for endocrine and non-endocrine tumors. At this time, insufficient data exists to justify the indication of “first-line” therapy. The principles of Somatostatin Receptor Imaging and radiotherapy are discussed in this article along with the current status of these modalities in clinical practice as viewed by the author.
Export Options
About this article
Cite this article as:
Podoloff A. Donald, Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393882
DOI https://dx.doi.org/10.2174/1381612023393882 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Chronic Hypercalcemia
Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued) Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry HSV-1 Viral Oncolysis and Molecular Imaging with PET
Current Cancer Drug Targets Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues
Protein & Peptide Letters Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Bioadhesive Films as Drug Delivery Systems
Drug Delivery Letters Roles of Perilipins in Diseases and Cancers
Current Genomics “What Is And What Should Never Be”<sup>#</sup>: Use and Misuse of HPV Testing in Cervical Cancer Prevention Strategies
Current Women`s Health Reviews Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets